Andy Darlington: Randomized Evidence for Catheter-Based Treatment of Intermediate-High-Risk PE
Andy Darlington, Global Partnerships Manager of Medical Devices at Radcliffe Group, shared a post on LinkedIn:
“In this clip, Prof Lukas Hobohm reviews the findings from the HI-PEITHO randomised controlled trial.
The trial compared EKOS plus anticoagulation with anticoagulation alone in 544 patients with intermediate-high-risk PE, assessing whether intervention could reduce early PE-related complications.
The discussion explores the reduction in the composite outcome of PE-related mortality, cardiopulmonary decompensation or PE recurrence within seven days, alongside findings on major bleeding and hospital length of stay.
Watch the clip below for insights into how randomised evidence is shaping treatment strategies for intermediate-high-risk PE.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?